Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
20.00K | 20.00K | 426.00K | -68.00K | 4.41M | 8.19M | Gross Profit |
-41.00K | 20.00K | -51.00K | -568.00K | 3.86M | -25.32M | EBIT |
-98.19M | -103.17M | -95.93M | -87.74M | -96.91M | -54.80M | EBITDA |
-90.75M | -94.81M | -87.94M | -84.40M | -96.53M | -54.15M | Net Income Common Stockholders |
-90.24M | -95.06M | -88.45M | -84.71M | -97.09M | -49.04M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
215.92M | 131.89M | 197.81M | 184.88M | 190.30M | 215.92M | Total Assets |
245.12M | 139.31M | 210.64M | 206.93M | 218.86M | 245.12M | Total Debt |
1.82M | 1.68M | 671.00K | 1.12M | 1.53M | 1.82M | Net Debt |
-114.09M | -35.24M | -134.45M | -109.97M | -188.77M | -114.09M | Total Liabilities |
19.24M | 15.80M | 16.54M | 21.64M | 19.73M | 19.24M | Stockholders Equity |
225.88M | 123.51M | 194.10M | 185.29M | 199.13M | 225.88M |
Cash Flow | Free Cash Flow | ||||
-80.33M | -79.85M | -75.86M | -62.71M | -90.55M | -34.65M | Operating Cash Flow |
-80.33M | -79.85M | -75.81M | -62.59M | -78.24M | -34.44M | Investing Cash Flow |
6.03M | -28.39M | 13.73M | -73.40M | 87.52M | -72.09M | Financing Cash Flow |
44.42M | 10.04M | 86.11M | 56.78M | 65.10M | 213.49M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $608.21M | 14.15 | 20.50% | ― | 2333.50% | ― | |
60 Neutral | $455.82M | ― | -57.28% | ― | -95.12% | 21.09% | |
55 Neutral | $622.77M | ― | -49.97% | ― | -14.16% | 25.80% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
51 Neutral | $477.59M | ― | 344.74% | ― | -47.32% | -26.67% | |
43 Neutral | $662.54M | ― | -48.45% | ― | ― | 7.15% | |
33 Underperform | $640.58M | ― | -71.44% | ― | ― | 19.94% |
On May 13, 2025, Altimmune entered into a Loan and Security Agreement with Hercules Capital, securing a $100 million credit facility to enhance its financial flexibility and support the development of its lead therapeutic candidate, pemvidutide. The company announced its first quarter 2025 financial results, reporting cash and short-term investments of $150 million as of March 31, 2025. Altimmune anticipates significant milestones in 2025, including top-line data from the IMPACT Phase 2b trial of pemvidutide in MASH, and the initiation of Phase 2 trials for AUD and ALD. These developments are expected to strengthen Altimmune’s position in the biopharmaceutical industry, particularly in addressing unmet medical needs in liver and cardiometabolic diseases.
The most recent analyst rating on (ALT) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.